$-0.27 EPS Expected for Inovio Pharmaceuticals, Inc. (INO); Kingold Jewelry (KGJI) Shorts Lowered By 3.29%

April 21, 2018 - By Henry Gaston

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Logo

Kingold Jewelry Inc (NASDAQ:KGJI) had a decrease of 3.29% in short interest. KGJI’s SI was 484,300 shares in April as released by FINRA. Its down 3.29% from 500,800 shares previously. With 53,200 avg volume, 9 days are for Kingold Jewelry Inc (NASDAQ:KGJI)’s short sellers to cover KGJI’s short positions. The SI to Kingold Jewelry Inc’s float is 1.07%. The stock increased 2.36% or $0.03 during the last trading session, reaching $1.3. About 24,266 shares traded. Kingold Jewelry, Inc. (NASDAQ:KGJI) has declined 1.63% since April 21, 2017 and is downtrending. It has underperformed by 13.18% the S&P500.

Analysts expect Inovio Pharmaceuticals, Inc. (NASDAQ:INO) to report $-0.27 EPS on May, 9.They anticipate $0.04 EPS change or 12.90% from last quarter’s $-0.31 EPS. After having $-0.24 EPS previously, Inovio Pharmaceuticals, Inc.’s analysts see 12.50% EPS growth. The stock increased 0.22% or $0.01 during the last trading session, reaching $4.64. About 848,977 shares traded. Inovio Pharmaceuticals, Inc. (NASDAQ:INO) has declined 24.44% since April 21, 2017 and is downtrending. It has underperformed by 35.99% the S&P500.

Kingold Jewelry, Inc. designs, manufactures, and sells gold jewelry and Chinese ornaments in the PeopleÂ’s Republic of China. The company has market cap of $85.95 million. It offers a range of in-house designed products, including gold necklaces, rings, earrings, bracelets, and pendants. It has a 3.33 P/E ratio. The firm sells its products under the Kingold brand directly to distributors, retailers, and other wholesalers.

Among 8 analysts covering Inovio Pharmaceuticals (NASDAQ:INO), 8 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Inovio Pharmaceuticals had 42 analyst reports since August 10, 2015 according to SRatingsIntel. On Tuesday, February 13 the stock rating was maintained by H.C. Wainwright with “Buy”. H.C. Wainwright maintained the stock with “Buy” rating in Tuesday, September 12 report. The firm earned “Buy” rating on Wednesday, March 21 by H.C. Wainwright. The rating was maintained by Stifel Nicolaus with “Buy” on Tuesday, August 8. The firm earned “Buy” rating on Wednesday, January 3 by H.C. Wainwright. Zacks downgraded the shares of INO in report on Wednesday, August 12 to “Hold” rating. The stock of Inovio Pharmaceuticals, Inc. (NASDAQ:INO) earned “Overweight” rating by PiperJaffray on Thursday, June 8. The rating was downgraded by Zacks to “Hold” on Friday, August 14. H.C. Wainwright maintained Inovio Pharmaceuticals, Inc. (NASDAQ:INO) rating on Friday, July 7. H.C. Wainwright has “Buy” rating and $1300 target. The rating was initiated by Citigroup with “Buy” on Wednesday, September 6.

Inovio Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops active DNA immunotherapies and vaccines in combination with proprietary electroporation delivery devices to prevent and treat cancers and infectious diseases. The company has market cap of $420.85 million. The Company’s SynCon immunotherapy design has the ability to break the immune system's tolerance of cancerous cells; and SynCon product design is also intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza. It currently has negative earnings. It has completed, current or planned clinical programs of its proprietary SynCon immunotherapies for HPV-caused pre-cancers and cancers, influenza, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus, hepatitis B virus, HIV, Ebola, Middle East Respiratory Syndrome, and Zika virus.

Kingold Jewelry, Inc. (NASDAQ:KGJI) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:

Recent Posts